Summit Therapeutics Inc. Cash Flow Statement
SMMT / Health Care|8 years of annual SEC 10-K data (FY2018-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 8 fiscal years. All figures from audited SEC 10-K filings.
Summit Therapeutics Inc. used $323M in operating cash flow and negative free cash flow of $324M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -$1.1B | -$221.3M | -$614.9M | -$88.6M | -$88.6M | -$52.7M | -$29.1M | $10.9M |
| Depreciation & Amortization | $146.0K | - | - | $330.0K | - | - | $321.0K | $409.0K |
| Operating Cash Flow | -$322.9M | -$142.1M | -$76.8M | -$72.6M | -$72.6M | -$48.1M | -$20.8M | -$35.1M |
| Capital Expenditures | $657.0K | $139.0K | $128.0K | $306.0K | $306.0K | $421.0K | $205.0K | $157.0K |
| Free Cash Flow | -$323.6M | -$142.2M | -$76.9M | -$72.9M | -$72.9M | -$48.5M | -$21.0M | -$35.3M |
| Dividends Paid | - | - | - | - | - | $0 | $0 | $0 |
| FCF Margin | - | - | - | -4029.5% | -4029.5% | -5643.3% | - | - |